Core Viewpoint - The acquisition of a 1.05% stake in Valgen Holding Corporation by Broncus China Holding Corporation for $15 million (approximately HKD 117 million) is seen as a strategic move to enhance the company's capabilities in comprehensive diagnosis and treatment of cardiopulmonary diseases [1]. Group 1: Acquisition Details - Broncus China Holding Corporation, a wholly-owned subsidiary of the company, has entered into a share transfer agreement with Qi Ming Medical (Hong Kong) Limited to acquire shares in Valgen Holding Corporation [1]. - The total consideration for the acquisition is $15 million, equivalent to approximately HKD 117 million [1]. - Valgen Holding Corporation is registered in the Cayman Islands and focuses on providing systemic solutions for mitral and tricuspid regurgitation diseases [1]. Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to achieve a comprehensive diagnosis and treatment platform for cardiopulmonary diseases [1]. - The company's expertise in chronic obstructive pulmonary disease (COPD) will complement the target group's offerings, facilitating the establishment of a robust foundation for integrated cardiopulmonary disease management [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Broncus Holding Corporation 於2025年12月29日，買方（本公司的全資附屬公司）與賣方訂立股份轉讓協議， 據此，賣方有條件同意出售，而買方有條件同意購買目標股份（佔目標公司截 至本公告日期按全面攤薄及轉換基準計算的發行在外股份的1.05%，總代價為 15,000,000美元（相等於約116.6百萬港元）。 上市規則的涵義 由於與收購事項相關的最高適用百分比率（定義見上市規則）超過5%但全部低於 25%，故收購事項及其項下擬進行的交易構成本公司一項須予披露交易，須根 據上市規則第14章遵守公告及申報規定。 股東及潛在投資者應注意，收購事項須待交割條件獲達成後方可作實，且未必 一定會完成。股東及潛在投資者於買賣本公司證券時務請審慎行事。 收購事項 於2025年12月29日，買方（本公司的全資附屬公司）與賣方訂立股份轉讓協議， 據此，賣方有條件同意出售，而買方有條件同意購買目標股 ...

Core Viewpoint - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award recognizes outstanding investor relations (IR) teams of listed companies for their significant contributions to industry transformation and development [4]. Group 1: Award Announcement - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award was presented during the "Technology Empowerment · Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1]. - Ten companies were awarded the "Annual Excellence IR Team (Small and Medium Market Capitalization)" award, including Beikang Medical-B (02170.HK), Gushengtang (02273.HK), Huitongda Network (09878.HK), Jinxin Fertility (01951.HK), Kunbo Medical-B (02216.HK), Lianlian Digital (02598.HK), Qingsi Games (06633.HK), TCL Electronics (01070.HK), Yaxin Technology (01675.HK), and Zhaoke Ophthalmology-B (06622.HK) [1]. Group 2: Evaluation Criteria - The award evaluation focused on the construction of communication channels between IR teams and investors, emphasizing the importance of long-term perspectives on companies' overall performance [4]. - The selection process involved quantitative data analysis and expert review to determine the final results [4]. Group 3: Broader Context - Gelonghui aims to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 ...

Fundraising and Allocation - The total amount raised from the subscription is approximately HKD 326.9 million, with a net amount of about HKD 326.5 million after expenses, equivalent to a net issue price of approximately HKD 3.106 per share[6]. - 30% of the net proceeds (approximately HKD 98.0 million) will be allocated for the development and commercialization of the targeted lung denervation system (TLD system), covering technology iteration, clinical trials, and marketing[6]. - 35% of the net proceeds (approximately HKD 114.2 million) will fund the key technology development for the natural orifice flexible surgical robot, with clinical trials expected to be completed by 2029[6]. - 20% of the net proceeds (approximately HKD 65.3 million) will be used to establish an overseas headquarters in Ireland, focusing on obtaining overseas regulatory approvals and commercializing core products[6]. - 15% of the net proceeds (approximately HKD 49.0 million) will be allocated for the company's working capital and other general corporate purposes, expected to be fully utilized by 2028[6]. Regulatory and Operational Updates - The company is currently in the approval process for necessary consents related to the subscription agreement, with submissions made to the relevant regulatory authorities in China[4]. - The company plans to provide further announcements regarding the completion of the subscription at an appropriate time[5]. - The overseas headquarters will integrate and coordinate existing overseas operations, enhancing management of international business activities[6]. - The company aims to commercialize the BroncAblate® system in China by the first half of 2025, following approval from the National Medical Products Administration (NMPA)[6]. Executive Compensation - The company has not granted restricted share units to any of the top five highest-paid individuals for the year ending December 31, 2024, except for the executive director and CEO Xu Hong[7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 ...

Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]

Core Viewpoint - Kintor Pharmaceutical-B (02216) has seen a significant increase in stock price, rising over 9% during trading, with a current price of 3.25 HKD and a trading volume of 11.79 million HKD. The company announced plans to issue a total of 105 million subscription shares at a price of 3.11 HKD per share, representing a premium of approximately 1.3% over the previous closing price. The net proceeds of approximately 327 million HKD will be used for potential acquisitions in the medical device industry, as the company seeks to expand its product portfolio [1][1][1]. Group 1 - Kintor Pharmaceutical plans to issue 105 million subscription shares at 3.11 HKD each, raising approximately 327 million HKD for acquisitions [1][1][1]. - The stock price of Kintor Pharmaceutical has increased by over 9% during trading, reflecting positive market sentiment [1][1][1]. - The company is currently in discussions with various parties to identify potential acquisition targets in the medical device sector [1][1][1]. Group 2 - Ying Tai Medical (01501) intends to invest approximately 283 million HKD to subscribe for about 91.09 million shares of Kintor Pharmaceutical [1][1][1]. - The subscription is expected to enhance Kintor Pharmaceutical's strategic positioning in the non-vascular interventional field, where it already has a rich product line [1][1][1].

Core Viewpoint - The company, KPB Medical-B (02216.HK), has entered into a subscription agreement to issue 105.1 million shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the closing price of HKD 3.07 [1][2] Group 1: Subscription Details - The total number of shares to be issued represents about 19.90% of the company's existing share capital as of the announcement date and approximately 16.60% of the enlarged share capital post-issuance [1] - The subscription is backed by two parties: Shanghai Yingtai Medical Devices Co., Ltd., which is engaged in the manufacturing of cardiovascular interventional medical devices, and Hangzhou Linheng Qingrui Enterprise Management Partnership, focusing on enterprise management and development services [1] Group 2: Financial Implications - The total gross proceeds from the subscription are estimated to be approximately HKD 326.9 million, with net proceeds expected to be around HKD 326.5 million after expenses, translating to a net issue price of about HKD 3.106 per share [2] - The net proceeds are intended to fund potential acquisitions in the medical device industry to expand the product portfolio, thereby strengthening the company's liquidity and financial position [2] - The board believes that the subscription will enhance the equity base of the company, optimize its capital structure, and support sustainable development, aligning with the overall interests of the company and its shareholders [2]

Core Viewpoint - The company, Kubo Medical-B (02216), has entered into a subscription agreement to issue and allot a total of 105 million subscription shares at a price of HKD 3.11 per share, which represents a premium over the market price on the date of the announcement [1] Group 1: Subscription Details - The total number of subscription shares to be issued represents approximately 16.60% of the enlarged issued share capital of the company, assuming no changes in the issued share capital from the date of the announcement until completion, except for the shares arising from the subscription [1] - The subscription price of HKD 3.11 per share is approximately 1.3% higher than the closing price of HKD 3.07 per share on the Hong Kong Stock Exchange on the date of the announcement [1] Group 2: Financial Implications - The estimated net proceeds from the subscription, after deducting expenses, are approximately HKD 327 million, equating to a net issue price of about HKD 3.106 per subscription share [1] - The net proceeds are intended to fund potential acquisitions in the medical device industry to continuously expand the company's product portfolio [1]